“I have known Brian for more than 12 years. I have worked with him both at Vertex and Lexicon. At Vertex, Brian has the reputation of being one of the most talented biologists. At Lexicon, Brian and I worked on the same project collaborating with BMS, and he was the project leader. Brian is approved to be an excellent leader, defined by superior organizational skills, effective communication capabilities and comprehensive understanding of project issues. Moreover, Brian is considered as kinase expert, and he was in charge of selecting and developing all the in-house biochemical and cell assays, either on-target or off-target enzymes, and managing AMBIT and CEREP panel profiling. Finally, Brian listens well, is very approachable with suggestions and acts on them. I would strongly recommend Brian for any employer who would benefit tremendous growth from adding him to the crew.”
About
Activity
-
I’m happy to share that I've been promoted to Senior Scientist II at HotSpot Therapeutics, Inc. !
I’m happy to share that I've been promoted to Senior Scientist II at HotSpot Therapeutics, Inc. !
Liked by Brian Hamman
-
Sharon Townson and John Castle comment on our groundbreaking work recently featured on the cover of Science Magazine. We’ve shown the molecular glue…
Sharon Townson and John Castle comment on our groundbreaking work recently featured on the cover of Science Magazine. We’ve shown the molecular glue…
Liked by Brian Hamman
-
HotSpot team members are celebrating the holiday weekend presenting preclinical data from our CBM signalosome inhibitor program at ESMO GI…
HotSpot team members are celebrating the holiday weekend presenting preclinical data from our CBM signalosome inhibitor program at ESMO GI…
Liked by Brian Hamman
Experience & Education
-
HotSpot Therapeutics, Inc.
View Brian’s full experience
See their title, tenure and more.
or
Volunteer Experience
-
Member of the Board of Directors
Open Genomes Foundation, Inc. (USA)
- Present 10 years 7 months
Science and Technology
http://www.open-genomes.org
-
Co-Founder, Board of Directors
Open Genomes e.V. (Germany)
- Present 10 years 10 months
Science and Technology
Assisted in registration within the European Union (VR 4903, Wiesbaden DE).
-
Group Administrator for 12 different projects covering over 5000 participants.
Family Tree DNA
- Present 22 years 6 months
Science and Technology
Publications
-
Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain.
Journal of Pharmacology and Experimental Therapeutics
See publicationCo-first author on this first manuscript describing project that went from gene KO to novel drugs in Phase 2b human trials as of Dec 2024.
-
The Discovery and Development of LX7101, A Dual LIM-kinase and ROCK Inhibitor for the Treatment of Glaucoma
ACS Medicinal Chemistry Letters
See publicationDescribes drug that completed Phase 1 human trials for Glaucoma
-
Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation
ACS Medicinal Chemistry Letters
-
Genetic Inhibition of Mst1 Alters T cell Function and Protects against Autoimmunity
PLOS ONE
See publication2nd author; project co-lead from start to finish, resulted in two clinical candidates for rheumatoid arthritis and multiple sclerosis.
-
A High-throughput Screen for Receptor Protein Tyrosine Phosphatase-gamma Selective Inhibitors.
Journal of Biomolecular Screening
-
Novel class of LIM-kinase 2 Inhibitors for the Treatment of Ocular Hypertension and Associated Glaucoma.
Journal of Medicinal Chemistry
See publicationRegarding the project that resulted in a drug that completed Phase 1 human trials for Glaucoma
-
A Homogeneous G Protein-coupled Receptor Ligand Binding Assay Based on Time-resolved Fluorescence Resonance Energy Transfer.
Assay and Drug Development Technologies
-
A FRET-Based In Vitro Assay for both Tyrosine- and Serine/Threonine-Specific Kinases and Phosphatases.
Assay and Drug Development Technologies
See publicationFirst manuscript shown in the inaugural issue of this well respected journal. First paper describing what is still known today as the Z'-Lyte assay technology. This paper is cited over 200 times. Primary inventor as shown in my notebook and the patent. Wrote the 1st draft of this manuscript.
-
Binding of a Pleckstrin Homology Domain Protein to Phosphoinositide in Membranes: A Miniaturized FRET-Based Assay for Drug Screening.
Journal of Biomolecular Screening
See publicationFirst and senior author.
Patents
-
Compounds, compositions and methods of treating disorders
Filed WO2024077244 A1
Primary author and contributor
-
PROTEIN-PROTEIN INTERACTION INDUCING TECHNOLOGY
Filed US 62/318,630
See patentDesigned and performed experiments for the first ever observations of a PROTAC-induced ternary complex of two proteins as detected by AlphaLISA and SPR. This patent describes the concept, proof, and utility of chemically-induced protein/protein interaction....
-
Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use
Issued WO2015035167A1
See patentMy group contributed all of the biochemical and cell based assay data to this patent. As co-leader of the project, made extensive intellectual contributions from target identification/validation, lead optimization DMPK, and in vivo pharmacology experiments.
-
Biaryl Kinase Inhibitors
Issued US 8,969,564, US-10723734-B2
See patentMy group contributed all of the biochemical and cell based assay data to this patent. As biology lead on the project, made extensive intellectual contributions from target identification/validation, lead optimization DMPK, and in vivo pharmacology experiments.
-
Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
Issued US 8,946,415, WO2015035117A1
See patentMy group contributed all of the biochemical and cell based assay data to this patent. As biology lead on the project, made extensive intellectual contributions from target identification/validation, lead optimization DMPK, and in vivo pharmacology experiments.
-
INHIBITION OF ADAPTOR ASSOCIATED KINASE 1 FOR THE TREATMENT OF PAIN
Issued US 20140080834 A1
See patentMy group contributed all of the biochemical and cell based assay data to this patent. As biology lead on the project, made extensive intellectual contributions from target identification/validation, lead optimization DMPK, and in vivo pharmacology experiments.
-
Substituted pyrrolo[2,3-d]pyrimidines as LIM kinase 2 inhibitors
Issued US 7,423,023
See patentMy group contributed all of the biochemical and cell based assay data to this patent. As co-leader of the project, made extensive intellectual contributions from target identification/validation, lead optimization DMPK, and in vivo pharmacology experiments.
-
MST1 kinase inhibitors and methods of their use
Issued US 8,440,652
See patentMy group contributed all of the biochemical and cell based assay data to this patent. As co-leader of the project, made extensive intellectual contributions from target identification/validation, lead optimization DMPK, and in vivo pharmacology experiments.
-
LIMK2 inhibitors, compositions comprising them, and methods of their use
Issued US 8,193,202
See patentMy group contributed all of the biochemical and cell based assay data to this patent. As co-leader of the project, made extensive intellectual contributions from target identification/validation, lead optimization DMPK, and in vivo pharmacology experiments.
-
Optical Probes and Assays
Issued US US 6410255 B1
See patentZ'-Lyte assay technology, invented during my first few months at Aurora Biosciences (31 claims), covering over 230 assays currently sold by Thermo Fisher (as of 2023). This technology is still widely used in the drug discovery industry today, primarily for protein kinases but also for enzymes responsible for other types of post-translational modifications.
-
Brm targeting compounds and associated methods of use
Filed US20190300521A1, US20200038378A1,
See patentMy group contributed all of the biochemical and cell based assay data to this patent. As biology lead on the project, made extensive intellectual contributions from target identification/validation, lead optimization assays, DMPK, and in vivo pharmacology experiments.
-
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
Filed US11065231B2
See patentBiology lead for this project, my group contributed all of the biochemical and cell based assay data to this patent application.
Honors & Awards
-
MTS in Drug Discovery
NIH, SBIR grant
Principal Investigator. Top ranked SBIR grant in year 2000. This work involved investigating translocation of MTS/peptide-tagged fusion proteins into cells.
Recommendations received
2 people have recommended Brian
Join now to viewMore activity by Brian
-
Inhibition of KRAS is not enough, especially for CRC! KRASi potently suppressed the cancer cell proliferation, but it rarely induced apoptosis…
Inhibition of KRAS is not enough, especially for CRC! KRASi potently suppressed the cancer cell proliferation, but it rarely induced apoptosis…
Liked by Brian Hamman
-
As a result of nerve damage in one’s hands and feet, patients with diabetic peripheral neuropathy (DPN) often experience tingling or burning…
As a result of nerve damage in one’s hands and feet, patients with diabetic peripheral neuropathy (DPN) often experience tingling or burning…
Liked by Brian Hamman
-
Great success in our IRF5 program, #proud of team drugging such an important immunology transcription factor! https://lnkd.in/eYWbSkzT
Great success in our IRF5 program, #proud of team drugging such an important immunology transcription factor! https://lnkd.in/eYWbSkzT
Liked by Brian Hamman
-
Next week, my colleague and I will present our research at ESMO GI 2025. For the first time, we will reveal the essential role of CBM signalosome in…
Next week, my colleague and I will present our research at ESMO GI 2025. For the first time, we will reveal the essential role of CBM signalosome in…
Liked by Brian Hamman
-
A reminder that proteins are highly dynamic molecules. Static protein structures are useful, as long as we remember that they capture only one…
A reminder that proteins are highly dynamic molecules. Static protein structures are useful, as long as we remember that they capture only one…
Liked by Brian Hamman
-
Cryo-electron microscopy (cryo-EM) has revolutionized structural biology, earning the 2017 Nobel Prize "for developing cryo-electron microscopy for…
Cryo-electron microscopy (cryo-EM) has revolutionized structural biology, earning the 2017 Nobel Prize "for developing cryo-electron microscopy for…
Liked by Brian Hamman
-
Shout out to #TeamAtlas for their showing at a very humid 2025 J.P. Morgan Corporate Challenge! #smilesandmiles #JPMCC #RunningAtlas
Shout out to #TeamAtlas for their showing at a very humid 2025 J.P. Morgan Corporate Challenge! #smilesandmiles #JPMCC #RunningAtlas
Liked by Brian Hamman
-
Thank you, Jon, Hayden, and Team for continuing to do this. I urge folks to print the poster to 4' x 6' and hang it up where you do your medicinal…
Thank you, Jon, Hayden, and Team for continuing to do this. I urge folks to print the poster to 4' x 6' and hang it up where you do your medicinal…
Liked by Brian Hamman
-
So what do we do after subcellular imaging of the entire Transcriptome? Well, how about we start working on imaging the whole PROTEOME! Check out…
So what do we do after subcellular imaging of the entire Transcriptome? Well, how about we start working on imaging the whole PROTEOME! Check out…
Liked by Brian Hamman
-
If you follow any of my lab’s work on the advent and development of photocatalytic proximity labeling, take a moment to check out a new study we…
If you follow any of my lab’s work on the advent and development of photocatalytic proximity labeling, take a moment to check out a new study we…
Liked by Brian Hamman
-
Great day with the Lexicon Pharmaceuticals, Inc. leadership team yesterday to align and reinforce our strategy for H2 as we advance the programs and…
Great day with the Lexicon Pharmaceuticals, Inc. leadership team yesterday to align and reinforce our strategy for H2 as we advance the programs and…
Liked by Brian Hamman
-
We are pleased to announce the FDA clearance of an Investigational New Drug application for MRT-8102 – a NEK7-directed molecular glue degrader being…
We are pleased to announce the FDA clearance of an Investigational New Drug application for MRT-8102 – a NEK7-directed molecular glue degrader being…
Liked by Brian Hamman
-
We’re thrilled to announce a major milestone for Auron Therapeutics: the first patient has been dosed in our Phase 1 clinical trial of AUTX-703 for…
We’re thrilled to announce a major milestone for Auron Therapeutics: the first patient has been dosed in our Phase 1 clinical trial of AUTX-703 for…
Liked by Brian Hamman
-
We’re pleased to announce that we’ve submitted our first ever New Drug Application to the U.S. FDA with our partner at Pfizer. The submission is…
We’re pleased to announce that we’ve submitted our first ever New Drug Application to the U.S. FDA with our partner at Pfizer. The submission is…
Liked by Brian Hamman
Other similar profiles
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top contentOthers named Brian Hamman in United States
-
Brian Hamman
-
Brian Hamman
-
Brian Hamman
Christ follower, husband, father, county commissioner
-
Brian Hamman
Financial Institution Examiner at Federal Deposit Insurance Corporation (FDIC)
15 others named Brian Hamman in United States are on LinkedIn
See others named Brian Hamman